The FDA confirmation de-risks the near-term regulatory path for the Helix catheter, a key platform asset. Traders should watch for the follow-on De Novo pre-submission filing this quarter and any subsequent FDA feedback, which will determine the binary outcome. The stock's small $15M market cap amplifies the impact of this catalyst.
Price Chart
Executive Summary
BioCardia announced that the FDA has confirmed and accepted the meeting minutes from its May 2026 Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System, ratifying the regulatory path forward. The company plans to submit a follow-on De Novo pre-submission this quarter, which, if successful, could lead to independent market clearance for the Helix catheter and enhance partnering opportunities. This is a positive regulatory milestone for a $15M market cap company, but the outcome remains binary and dependent on FDA approval.
Key Facts
- FDA confirmed and accepted the meeting minutes from BioCardia's May 2026 Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System.
- BioCardia intends to submit a follow-on De Novo pre-submission for Helix approval this quarter (Q3 2026).
- Successful Helix market clearance could enable independent commercialization and enhance development and commercial partnering for cell, gene, and protein therapeutics.
- Upcoming catalysts include a CardiAMP Cell Therapy Japan PMDA submission in Q4 2026 and Helix FDA Pre-Sub Amendment in Q3 2026.
Financial Impact
No financial figures provided; the filing is a regulatory milestone update with no revenue or earnings data.
Risk Factors
- FDA may not approve the De Novo submission, preventing market clearance.
- BioCardia's liquidity position and ability to fund operations and clinical trials remain a risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-028778 |
| Document: 0001437749-26-028778-index.html | 0001437749-26-028778 |
| Document: 0001437749-26-028778.txt | 0001437749-26-028778 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.8975 $1.04 | ▲ +15.88% | ▲ +15.54% | $0.9200 (+2.51%) |
Oct 19, 2026 7d ago | Press Release | $0.9000 $1.04 | ▲ +15.56% | ▲ +15.22% | $0.9200 (+2.22%) |
Oct 7, 2026 19d ago | 8-K | $1.09 $1.06 | ▼ −2.75% | ▼ −2.33% | $0.9200 (−15.60%) |
Oct 1, 2026 25d ago | 8-K | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9200 (−9.80%) |
Oct 1, 2026 25d ago | Press Release | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9200 (−9.80%) |
Sep 23, 2026 4w ago | 8-K | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9200 (−12.38%) |
Sep 23, 2026 4w ago | Press Release | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9200 (−12.38%) |
Sep 10, 2026 6w ago | 8-K | $1.10 $1.08 | ▼ −1.82% | ▼ −2.67% | $0.9200 (−16.36%) |
Aug 24, 2026 9w ago | 8-K | $1.06 $1.13 | ▲ +6.60% | ▲ +6.28% | $0.9200 (−13.21%) |
Aug 5, 2026 11w ago | Press Release | $0.9500 $0.9496 | ▼ −0.04% | ▲ +0.12% | $0.9200 (−3.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers